We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.

Take a look at our previous reports:

Annual Report

2016

View Report

Q1 Report

2017

View Report

H1 Report

2017

View Report

Q3 Report

2017

View Report
English | Dutch
Jump to content [AK + s] Jump to navigation [AK + 3]

Annual Report 2017

  • Twitter
  • LinkedIn

Primary Menu

  • The Galapagos group
    • Letter from the management
    • At a glance
    • Strategy
    • Corporate social responsibility
    • Going concern statement
    • Risk management and internal control
    • The Galapagos share
    • Subsequent events
    • Overview of Galapagos NV
    • Disclaimer and other information
  • R&D
    • The Galapagos pipeline
    • Target discovery platform
    • Filgotinib
      • Our filgotinib program in RA
      • Inflammatory bowel disease
        • Our filgotinib program in IBD
        • Clinical program with filgotinib in CD
        • Clinical program with filgotinib in UC
      • Other clinical programs with filgotinib
    • Idiopathic pulmonary fibrosis
    • Cystic fibrosis
      • Clinical program for CF
    • Osteoarthritis
    • Atopic dermatitis
  • Risk factors
    • Financial position and need for additional capital
    • Product development, regulatory approval and commercialization
    • Reliance on third parties
    • Competitive position
    • Intellectual property
    • Organization, structure and operation
    • Galapagos shares
    • General statement
  • Corporate governance
    • Policies
    • Board of directors
    • Committees
    • Share capital and shares
    • Shareholders
    • Remuneration report
      • Determination of remuneration
      • Remuneration policy
      • Non-executive directors
      • Executive directors
      • Criteria and methods to evaluate performance
      • Gross remuneration of CEO
      • Gross remuneration of other executive committee members
      • Shares, warrants or other rights
      • Provisions for severance
      • Severance payments in 2017
      • Claw-back right
    • Conflict of interests and related parties
    • Code of Business Conduct and Ethics
    • Statement by the board of directors
  • Financial statements
    • Consolidated financial statements
      • Statements of income and comprehensive income
      • Statements of financial position
      • Cash flow statements
      • Statements of changes in equity
    • Notes to the consolidated financial statements
      • Notes 1-10
        • 1. General information
        • 2. Significant accounting policies
        • 3. Critical accounting estimates and judgments
        • 4. Segment information
        • 5. Total revenues and other income
        • 6. Operating costs
        • 7. Staff costs
        • 8. Fair value re-measurement of share subscription agreement
        • 9. Other financial income/expenses
        • 10. Taxes
      • Notes 11-20
        • 11. Income/loss per share
        • 12. Intangible assets
        • 13. Property, plant and equipment
        • 14. Other non-current assets
        • 15. Research and development incentives receivables
        • 16. Restricted cash
        • 17. Trade and other receivables and other current assets
        • 18. Cash and cash equivalents
        • 19. Share capital
        • 20. Other reserves
      • Notes 21-30
        • 21. Translation differences
        • 22. Deferred tax
        • 23. Trade and other liabilities
        • 24. Deferred income
        • 25. Operating lease obligations
        • 26. Off-balance sheet arrangements
        • 27. Contingent assets and liabilities
        • 28. Retirement benefit plans
        • 29. Warrant plans
        • 30. Related parties
      • Notes 31-34
        • 31. Consolidated companies as of 31 December 2017
        • 32. Financial risk management
        • 33. Statutory auditor’s remuneration
        • 34. Events after balance sheet date
    • Non-consolidated financial statements
  • Auditor's report
    • Report of the statutory auditor

GLPG1690

proof of platform in idiopathic pulmonary fibrosis

You are here:

  • Home
  • Risk factors

Risk factors

Risk factors
Galapagos NV • Annual Report 2017
previous pagenext page

Financial position and need for additional capital

Read more

Risks related to our competitive position

Read more

Risks related to our intellectual property

Read more
to page top

Service

  • Glossary of terms
  • Downloads
  • Financial calendar
  • Galapagos Corporate Website

Last Update 23 March 2018

Galapagos Annual Report 2017 (PDF)

Download the entire report as PDF.

Download PDF (3.5 MB)
English | Dutch
  • Downloads
  • Glossary of terms
  • © Copyright 2018 Galapagos NV
  • Colophon
  • Contact
  • Privacy notice
© Copyright 2018 Galapagos NV
nexxar - digital reporting evolved - Online Report